#Latin America Healthcare#GlobalData#Hospital Finance#Mexi

Mexico’s Healthcare Market to Reach $28 Billion by 2020

According to a recent report by GlobalData and the Organization for Economic Co-operation and Development, Mexicos pharmaceutical and medical devices in...

Admin
|Aug 11|magazine6 min read

According to a recent report by GlobalData and the Organization for Economic Co-operation and Development, Mexico’s pharmaceutical and medical devices industries will be worth approximately $22.5 billion and $5.4 billion by 2020, respectively. Overall, Mexico’s healthcare market will reach a value of $27.9 billion.

Mexico’s healthcare market value will represent a Compound Annual Growth Rate of 6.8 percent, climbing from $17.6 billion in 2013, the report stated.

According to GlobalData, a number of factors, including the prevalence of non-communicable diseases, improvements in regulatory healthcare guidelines, government support for the healthcare sector, and the North American Free Trade Agreement, will help drive the anticipated market growth.

“Over 350 domestic and multi-national companies are engaged in the manufacture of pharmaceutical products in Mexico, making the country one of the leading producers in the Americas. During the next five years, the pharmaceutical sector will have the opportunity to expand, due to a number of branded drugs losing market exclusivity. This will benefit domestic manufacturers, as the top pharmaceutical companies in Mexico mostly deal with generic drugs,” said Joshua Owide, GlobalData’s director of Healthcare Industry Dynamics, in a news release.

Mexico was Latin America’s main exporter of pharmaceutical products in 2012, and the country has grown to be a key exporter to Europe and the U.S., thanks largely in part to free trade agreements.

“While the Mexican pharmaceutical market may be vulnerable, with a high share of private healthcare expenditure, alongside out-of-pocket payments and the problem of counterfeit drugs, the overall outlook remains bright,” said Owide. “Non-communicable disease, which is rising in prevalence due to the increasing elderly population and changes to diet and lifestyle, combined with the Mexican government’s aim to provide universal healthcare coverage, will increase public expenditure and create greater market opportunities for both the pharmaceutical and medical device industries.”